Marilyn Justice
Family · Newport, TNNPI 1700459286
Payments from drug & device makers
Across 83 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$190
- AbbVie$185
- Bayer$148
- Novo Nordisk$132
- Lilly USA, LLC$109
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$91
- plus $595 from 18 others
What the payments were for
- Food & beverage$1,449100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 9 | $190 |
| AbbVie | 9 | $185 |
| Bayer | 9 | $148 |
| Novo Nordisk | 7 | $132 |
| Lilly USA, LLC | 7 | $109 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $91 |
| GSK | 5 | $81 |
| Pfizer | 4 | $74 |
| Esperion Therapeutics, Inc. | 4 | $58 |
| Otsuka America Pharmaceutical, Inc. | 3 | $53 |
| Mylan Specialty L.p. | 3 | $51 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| Sumitomo Pharma America, Inc. | 2 | $32 |
| Corcept Therapeutics | 2 | $29 |
| Boehringer Ingelheim | 2 | $27 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Amgen | 1 | $20 |
| Merck | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Alkermes, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Shield Therapeutics Inc | 1 | $15 |
| Gilead | 1 | $13 |
| Echosens North America, Inc. | 1 | $11 |
How this compares
$1,449 in reported general payments places this provider in the 70th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 48 | $68,267 |
| OzempicSemaglutide | 30 | $59,002 |
| JardianceEmpagliflozin | 50 | $51,016 |
| MounjaroTirzepatide | 18 | $28,524 |
| EliquisApixaban | 19 | $24,525 |
| VraylarCariprazine Hcl | 13 | $21,720 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $19,558 |
| Spiriva RespimatTiotropium Bromide | 17 | $17,415 |
| GemtesaVibegron | 12 | $12,574 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,914 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $5,080 |
| Gabapentin | 125 | $3,210 |
| Dimethyl Fumarate | 14 | $2,516 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 54 | $1,627 |
| NitrofurantoinNitrofurantoin Macrocrystal | 12 | $1,362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $27 | $68,43167 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $53 | $68,26748 claims |
| Novo NordiskOzempic | $132 | $59,00230 claims |
| Lilly USA, LLCMounjaro | $109 | $28,52418 claims |
| PfizerEliquis | $74 | $24,52519 claims |
| AbbVieVraylar | $185 | $21,72013 claims |
| GSKTrelegy Ellipta | $81 | $19,55830 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $32 | $12,57412 claims |
| AstraZenecaSymbicort | $190 | $5,08011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,706 family providers in Tennessee.
Other family in Newport
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.